Pemphigus Vulgaris (PV) is an autoimmune disease characterized by vesicles and bullae onthe skin and mucosa resulting from an autoantibody reaction to desmosomal adhesion moleculesdesmoglein (Dsg) 1 and 3, which function as strong adhesions between keratinocytes. PemphigusVulgaris is more common in the fifth and sixth decades of age. The lesions are fragile blisters on themucosa and skin. Diagnosing PV requires anamnesis, physical examination, and investigations suchas histopathologic examination and direct immunofluorescence. Therapy generally uses steroids.Adjuvant treatment is given to reduce the side effects of corticosteroids. We reported a male, 59 yearsold, was treated with blisters that break easily into blisters on the head, face, chest, back, groin andbuttocks accompanied by burning and itching. In the scalp, facial, anterior et posterior trunk, inguinal,and gluteal regions, multiple erythematous macules were found with lenticular-plaque shape; it waspartially confluent with thick brown crusts which were challenging to remove. The histopathologicexamination found the presence of suprabasal bullae with lymphocyte inflammation cells. The patientwas diagnosed with PV and treated with corticosteroids with the sparing agent mycophenolate sodiumand showed clinical improvement. The first-line treatment for pemphigus Vulgaris is systemiccorticosteroids. Adjuvant sparing agent therapy is given to reduce the side effects of corticosteroids.Sodium mycophenolate sparing agent was selected because of its minimum side effects. In systemicmanagement, the dose of corticosteroid and sparing agent mycophenolate sodium was graduallydecreased. The patient experienced initial remission after treatment
A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis
